September 16, 2026 – TheNewswire - CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) is pleased to announce the following corporate actions.

Based on a previous announcement for approval of our European patent, CTT has moved forward with a Unitary patent which covers 18 European Union member states.  The company also plans to validate the patent in additional countries which are covered by the Unitary Patent.

The CEO of CTT Pharma has initiated a plan to change his employment contract with the company to a performance based one in an effort to limit shareholder dilution and preserve capital. This new contract will include milestones such as FDA approvals, specific price targets of the company’s share price, partnerships, licensing, revenue and will go into effect for the 1st Quarter of 2027.

The company signed a term sheet with a hedge fund outlining a potential capital raise. If additional funding is raised, CTT will apply this capital towards manufacturing, potential clinical trials, and corporate expenses. CTT is in contract discussions with a U.S. company to conduct clinical trials for a smoking cessation product. These contract discussions are a continuation of a signed Letter of Intent(LOI) between both companies. CTT Pharma Is currently in talks with a manufacturer to help develop the company’s patented technology and mass produce several potential product lines. Additionally, CTT is in discussions with a University in the United States for a possible partnership. The company will continue to notify shareholders as more news becomes available and will file necessary 8-K forms with the SEC when applicable.

 

About CTT Pharmaceutical Holdings, Inc.

CTT Pharmaceutical Holdings, Inc. is a pharmaceutical technology company specializing in oral drug delivery systems designed to provide rapid onset, enhanced patient convenience, and efficient absorption. The Company’s patented micelle based thin film platform is intended to offer a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is focused on integrating scientific validation, scalable manufacturing, and regulatory preparedness to support long-term growth and product innovation.

Forward-Looking Statements

Forward-looking statements include statements regarding the Company’s plans, objectives, expectations, and intentions, including potential future business operations. Words such as anticipate, believe, continue, could, estimate, expect, intend, may, plan, potential, predict, should, will, would and similar expressions identify forward-looking statements. These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in forward-looking statements. Important factors that could cause such differences include, but are not limited to: the timing and outcome of a potential partnership. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

CTT Pharmaceutical Holdings, Inc.

813-606-0060